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The impairment of astrocyte functions is associated with diabetes mellitus and other neurodegenerative diseases. Astrocytes have
been proposed to be essential cells for neuroprotection against elevated levels of methylglyoxal (MG), a highly reactive aldehyde
derived from the glycolytic pathway. MG exposure impairs primary astrocyte viability, as evaluated by different assays, and these
cells respond to MG elevation by increasing glyoxalase 1 activity and glutathione levels, which improve cell viability and survival.
However, C6 glioma cells have shown strong signs of resistance against MG, without significant changes in the glyoxalase system.
Results for aminoguanidine coincubation support the idea that MG toxicity is mediated by glycation. We found a significant
decrease in glutamate uptake by astrocytes, without changes in the expression of the major transporters. Carbenoxolone, a
nonspecific inhibitor of gap junctions, prevented the cytotoxicity induced by MG in astrocyte cultures. Thus, our data reinforce
the idea that astrocyte viability depends on gap junctions and that the impairment induced by MG involves glutamate
excitotoxicity. The astrocyte susceptibility to MG emphasizes the importance of this compound in neurodegenerative diseases,
where the neuronal damage induced by MG may be aggravated by the commitment of the cells charged with MG clearance.
1. Introduction
Astrocytes are essential for the survival and activity of neu-
rons in physiological and pathological conditions [1]. The
key role of astrocytes in the brain includes defense against
oxidative stress, regulation of the synthesis, release of gluta-
thione (GSH), glutamate uptake, and the modulation of
synaptic activity, amongst other mechanisms [2, 3]. Further-
more, the astrocyte network that is formed by gap junctions
is essential to the ionic and metabolic homeostasis of the
central nervous system, as astrocytes play a critical role in
maintaining the homeostatic regulation of extracellular pH,
K+, and glutamate levels [4].
Brain tissue is highly dependent on glucose, not only as
an energetic source but also for the synthesis of glutamate
and GSH. However, an elevated flow of glucose in the
brain tissue, as occurs in diabetes mellitus, can lead to
deviations from the glycolytic pathway, causing elevations
in methylglyoxal (MG), an extremely reactive aldehyde
that is involved in dicarbonyl stress and advanced glyca-
tion end product (AGE) formation from proteins, nucleic
acids, and lipids [5]. In this context, the glyoxalase system
is important for detoxifyingMG and, therefore, for maintain-
ing MG concentrations under control, in turn, preventing
AGE formation [6].
We have investigated the effects of MG exposure on C6
glioma cells [7], acute brain slices [8], and on rat behavior
in vivo [9]. However, only a few studies have investigated
the effect of MG on isolated astrocytes and, consequently,
on their specific activities. Data in the literature indicate that
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the impairment of astrocyte functions is linked to neuro-
degenerative diseases [10], such as Alzheimer’s disease,
where AGE accumulates in the neurons and astroglia, as well
as in amyloid plaques [11]. The importance of astrocyte-
mediated neuroprotection against elevated levels of MG has
been proposed [3].
Although astrocytes have a more developed glyoxalase
system than neurons, protecting them from dicarbonyl stress
[12, 13], it has been suggested that astrocytes are also dam-
aged by glycation processes in diabetes mellitus and neurode-
generative diseases [11, 14]. In fact, its direct effects on
astrocytes could aggravate the neuronal damage that is
induced by MG. We, herein, studied the direct susceptibility
of primary astrocyte cultures from Wistar rats to MG expo-
sure, evaluating specific changes in the glyoxalase system,
GSH content, glutamate uptake, and gap junction activity.
Moreover, we compared the results of primary astrocyte
cultures with those of C6 glioma cells, assuming eventual
differences between these two glial cultures.
2. Materials and Methods
2.1. Materials.Methylglyoxal (MG), propidium iodide, [3(4,5-
dimethylthi-azol-2-yl)-2,5-diphenyl tetrazolium bromide]
(MTT), neutral red, carbenoxolone disodium salt (CBX),
aminoguanidine hemisulfate salt (AG), standard glutathione,
o-phthaldialdehyde, metaphosphoric acid, L-glutamate, N-
methyl-D-glucamine, 4-(2-hydroxyethyl) piperazine-L-
ethanesulfonic acid (HEPES), and cell culture materials were
purchased from Sigma (Saint Louis, MO, USA). Dulbecco’s
modified Eagle medium (DMEM) and Dulbecco’s
phosphate-buffered saline (DPBS) were purchased from Gibco
BRL (Carlsbad, CA, USA). Fetal bovine serum was obtained
from Cultilab (Campinas, SP, Brazil), and L-[2,3-3H] gluta-
mate was purchased from Amersham International (United
Kingdom). Polyclonal anti-EAAT1 (GLAST) and anti-
EAAT2 (GLT-1) were purchased from Abcam (Cambridge,
MA, USA), anti-EAAT3 was purchased from Novus Biologi-
cals (Littleton, CO, USA), and polyclonal anti-glyoxalase 1
was purchased from Santa Cruz Biotechnology Inc. (Dallas,
Texas, USA). All other chemicals were purchased from local
commercial suppliers.
2.2. Primary Astrocyte Culture. Primary astrocyte cultures
from Wistar rats were prepared as previously described
[15]. Procedures were in accordance with the National Insti-
tutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the local authorities. Briefly,
the cerebral cortex of newborn Wistar rats (1-2 days old)
were removed and mechanically dissociated in Ca2+- and
Mg2+-free Dulbecco’s phosphate-buffered saline (DPBS),
pH 7.2, containing (in mM) 137.93 NaCl, 2.66 KCl, 8.09
Na2HPO4, 1.47 KH2PO4, and 5.55 glucose. The cortex was
cleaned of meninges and mechanically dissociated by
sequential passage through a Pasteur pipette. After centrifu-
gation at 1400 rpm for 5min, the pellet was resuspended in
DMEM (pH 7.6) supplemented with 8.39mM HEPES,
23.8mMNaHCO3, 0.1% amphotericin B, 0.032% garamycin,
and 10% fetal bovine serum. Approximately 800,000,
300,000, or 50,000 cells were seeded in each well in 12-, 24-,
or 96-well plates, respectively, and maintained in DMEM
containing 10% fetal bovine serum in 5% CO2/95% air at
37°C. Cell were then allowed to grow to confluence and used
at 21 days. The medium was replaced by DMEM with 1%
fetal bovine serum in the absence or presence of MG. CBX
(0.1mM) was added 15min before MG exposure, and after-
wards, cells were coincubated with MG at 24 h. Coincubation
of MG and AG at 24h was also performed.
2.3. C6 Glioma Cell Culture. The C6 glioma cell line, an
astrocyte-like cell line, was obtained from the American Type
Culture Collection (Rockville, Maryland, USA). Late passage
cells, harvested after at least 100 passages, were seeded in 12-,
24-, or 96-well plates at densities of 20,000, 10,000, or 2000
cells/well, respectively, and cultured in DMEM (pH 7.6) sup-
plemented with 5% fetal bovine serum, 2.5mg/mL Fungi-
zone, and 100U/L gentamicin in 5% CO2/95% air at 37
°C.
After the cells had reached confluence, the culture medium
was replaced by DMEM without serum in the absence or
presence of MG [16]. CBX (0.1mM) was added 15min
before MG exposure, and cells were subsequently coincu-
bated with MG for 24 h. Coincubation of MG and AG for
24 h also was performed.
2.4. MTT Reduction Assay. Cells were treated with 0.5mg/mL
MTT for 30min in 5% CO2/95% air at 37°C. The medium
was then removed, and MTT crystals were dissolved in
DMSO. Absorbance values were measured at 560 and
650 nm. The reduction of MTT was calculated by the follow-
ing formula: [(abs 560nm)− (abs 650nm)] [17]. Results were
expressed as percentages of the control.
2.5. Neutral Red Incorporation Assay. Cells were treated with
50μg/mL neutral red (NR) for 30min in 5% CO2/95% air at
37°C. The cells were then rinsed twice with phosphate-
buffered saline (PBS) for 5min each time. The NR dye taken
up by viable cells was then extracted with 500μL of acetic
acid/ethanol/water (1/50/49, v/v). Absorbance values were
measured at 560nm [18]. Results were expressed as percent-
ages of the control.
2.6. Propidium Iodide Uptake Assay. At the end of treat-
ments, cells were incubated with 7.5μM propidium iodide
(PI) for 15min and viewed with a Nikon inverted microscope
with a TE-FM Epi-Fluorescence accessory. Images were
transferred to a computer with a digital camera [18]. Positive
cells were quantified using ImageG® software.
2.7. Evaluation of Glyoxalase System. The astrocytes or C6
cultures were first lysed and homogenized in sodium phos-
phate buffer, pH 7.4. Cell homogenates were then centrifuged
at 13000 rpm for 15min at 4°C, and the supernatant was used
for enzymatic activities and protein content measurements.
Glyoxalase 1 activity was then determined as previously
described [19] with some modifications. The assay was car-
ried out in 96-well microplates using a microplate spectro-
photometer (UV Star, Greiner). The reaction mixture
(200μL/well) contained 50mM sodium-phosphate buffer
(pH 7.2), 2mM MG, and 1mM GSH (preincubated for
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30min at room temperature). Protein from the sample (10–
20μg per well) was added to the buffer. The formation of S-
(D)-lactoylglutathione was linear and monitored at 240 nm
for 15min at 25°C. A unit of glyoxalase I activity is defined
as the amount of enzyme that catalyzes the formation of
1μmol of S-(D)-lactoylglutathione per minute. Specific activ-
ity was calculated and expressed as milliunits per milligram
of protein or expressed as a percentage of the control.
2.8. Glutathione (GSH) Content Assay. Intracellular GSH
levels (nmol/mg protein) were measured as previously
described [20]. This assay detects only the reduced glutathi-
one content. Cell homogenates were diluted in ten volumes
of 100mM sodium phosphate buffer, pH 8.0, containing
5mM EDTA, and protein was precipitated with 1.7%
metaphosphoric acid. Supernatant was assayed with o-
phthaldialdehyde (1mg/mL methanol) at room temperature
for 15min. Fluorescence was measured using excitation and
emission wavelengths of 350 and 420nm, respectively. A
calibration curve was formed using standard GSH solutions
(0–500μM). GSH concentration was expressed as the
percentage of the control.
2.9. Glutamate Uptake Assay. Glutamate uptake was per-
formed as previously described [21] with some modifica-
tions. Cells were briefly incubated at 37°C in a Hank’s
balanced salt solution (HBSS) containing (in mM) 137 NaCl,
5.36 KCl, 1.26 CaCl2, 0.41 MgSO4, 0.49 MgCl2, 0.63 Na2H-
PO4·7H2O, 0.44 KH2PO4, 4.17 NaHCO3, and 5.6 glucose,
adjusted to pH 7.2. The assay was initiated by the addition
of 0.1mM L-glutamate and 0.33μCi/mL L-[2,3-3H] gluta-
mate. The incubation was stopped after 7min for the astro-
cyte cultures and after 10min for the C6 cultures by
removing the medium and rinsing the cells twice with ice-
cold HBSS. Cells were then lysed in a 0.5M NaOH solution.
Sodium-independent uptake was determined using N-
methyl-D-glucamine instead of NaCl. Sodium-dependent
glutamate uptake was obtained by subtracting the nonspe-
cific uptake from the total uptake to obtain the specific
uptake. Radioactivity was measured in a scintillation counter.
Results were calculated as nmol/mg protein/min and were
expressed as percentages of the control.
2.10. Protein Determination. Protein content was measured
by Lowry’s method using bovine serum albumin as standard
[22].
2.11. Western Blot Analysis. After 24 h of MG addition, astro-
cytes or C6 cultures were processed for electrophoresis/
Western blotting by directly homogenizing in electrophoresis
sample buffer at pH 6.8 (containing 62.5mM Tris-HCl, 2%
(w/v) SDS, 5% (w/v) β-mercaptoethanol, 10% (v/v) glycerol,
and 0.002% (w/v) bromophenol blue) and boiling for 5min.
Protein samples (15μg per lane), prepared for electrophore-
sis as described above, were analyzed by 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to nitrocellulose membranes using a semidry
blotting apparatus (1.2mA/cm2; 1 h) [23]. The membranes
were blocked overnight or for 1 h at 4°C with 5% bovine
BSA in Tris-buffered saline (TBS) (10mM Tris, 150mM
NaCl, pH 7.5) and then incubated for 3 h with an anti-
GLAST, anti-GLT1, or anti-EAAT3 antibody (diluted
1 : 1000, 1 : 200, 1 : 1000, resp., in TBS containing Tween-20
and 2% BSA), or overnight at 4°C with an anti-glyoxalase 1
antibody (diluted 1 : 10,000 in TBS containing Tween-20
and 2% BSA). Next, for anti-GLAST, anti-GLT1, or anti-
EAAT3 antibody, membranes were incubated for 2 h at room
temperature with horseradish peroxidase- (HRP-) conju-
gated anti-mouse secondary antibody. Next, for anti-
glyoxalase 1, membranes were incubated for 1 h at 4°C with
horseradish peroxidase- (HRP-) conjugated anti-rabbit sec-
ondary antibody (1 : 10,000). Equivalent loading for each
sample was confirmed with antiactin (diluted 1 : 10,000 in
TBS containing Tween-20 and 2% BSA). The chemilumines-
cent reactions were developed using luminol as the substrate
(ECLWestern Blotting Analysis System, GE Healthcare) and
evaluated in the luminescence image analyzer (Image Quant
LAS4000 from GE). The immunocontent of GLAST, GLT1,
EAAT3, and glyoxalase 1 was determined for optical density.
The bands were quantified using ImageJ software.
2.12. Statistical Analysis. Data are reported as the mean ±
standard error and analyzed statistically by Student’s t-test
or by one-way ANOVA. Statistically significant one-way
ANOVA was followed by a post hoc Dunnett’s test. Data
were considered significant when p < 0 05. All analyses were
carried out using the SPSS software package or Prism 5.0
(GraphPad).
3. Results
3.1. Comparison of the Glyoxalase Systems in Primary
Astrocytes and C6 Glioma Cells. Hypothesizing that astro-
cytes and C6 glioma cells may present metabolic differences,
we measured the activity and content of glyoxalase 1, the
rate-limiting enzyme of the glyoxalase system, in both cell
types. The relative expressions and activities of glyoxalase
1 were significantly higher in astrocytes than in C6 cells
(3.3- and 0.7-fold, resp.) (Figures 1(a) and 1(b)). There-
fore, astrocytes present a 1.5-fold increase in glyoxalase 1
expression/activity ratio, when compared to C6 glioma
cells (Figure 1(c)).
3.2. High Concentrations of MG Compromise the Cell
Viability and Survival of Astrocytes and C6 Glioma Cells.
Astrocytes and C6 glioma cells were exposed to increasing
concentrations of MG (from 0.1 to 4mM) for 24 h; cell viabil-
ity was then evaluated by MTT reduction, neutral red (NR)
incorporation, and propidium iodide (PI) uptake assays
(Figure 2). No impairment in MTT reduction capacity was
observed up to 1mMMG; however, 2mMMG induced a sig-
nificant decrease (about 50%) in cell viability in both cell
types (Figure 2(a)). At the highest concentration of MG, we
observed a greater decrease in MTT reduction in astrocytes,
but curiously, we observed an increase in C6 glioma cells.
In contrast, using the NR uptake assay, no impairment
in cell viability was seen up to 1mM, while the highest
concentrations of MG significantly affected both cell types
(Figure 2(b)). With regard to PI incorporation, neither of
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the cell types presented PI staining with up to 1mM MG
(Figure 2(c)); however, 2mM MG induced a significant
increase in uptake and, in astrocytes, the damage was
higher at 4mM MG. Interestingly, once again in C6 gli-
oma cells, the highest concentration of MG cell survival
apparently improved cell viability. Based on these assays,
we chose intermediate concentrations of MG (0.4 or
1mM) for further experiments.
3.3. High MG Increases Glyoxalase 1 Activity in Astrocytes.
The incubation of astrocyte cultures with 1mM MG (but
not 0.4mM) for 24h increased glyoxalase 1 activity
(Figure 3(a)). This elevation was independent of the expres-
sion of glyoxalase 1 (Figure 3(c)). In contrast, we observed
no changes in the activity or in the immunocontent of glyox-
alase 1 in C6 glioma cells incubated with 0.4 or 1mM MG
(Figures 3(b) and 3(d)).
3.4. Elevated MG Augments Astrocyte GSH Content. Consid-
ering the importance of GSH as a cosubstrate for glyoxalase 1
activity, we measured possible changes in GSH content
induced by MG (Figure 4). Increased GSH content was
induced by the incubation of astrocytes with 1mM MG, but
not with 0.4mMMG (Figure 4(a)). Conversely, in C6 glioma
cells, we observed a small but significant decrease in GSH
content (Figure 4(b)).
3.5. Aminoguanidine Prevents the Effect of MG on Glyoxalase
1 Activity and GSH Content. In order to investigate whether
the effects of 1mM MG on glyoxalase 1 activity and GSH
content is mediated by glycation, astrocytes were coincu-
bated for 24h with aminoguanidine (AG), a well-known
antiglycation compound. AG per se did not alter glyoxalase
1 activity or GSH content (Table 1); however, this compound
prevented the augmentations in glyoxalase 1 activity and
GSH content.
3.6. MG Exposure Reduces Glutamate Uptake in Astrocytes,
without Changing Glutamate Transporter Expression. Astro-
cytes and C6 glioma cells were incubated with 0.4mM MG
(Figure 5) or 1mM (data not shown) for 24h. MG at both
concentrations similarly decreased glutamate uptake activity
(Figure 5(a)), and AG was able to prevent this decrease.
Importantly, decrease glutamate uptake in astrocytes was
not associated with changes in the contents of GLAST
(Figure 5(c)), GLT-1 (Figure 5(e)), or EAAT3 (Figure 5(g)),
as determined by Western blotting. Notice that an apparent
decrease in the GLAST expression, observed in Figure 5(c),
was not statistically significant (by Student’s t-test,
p = 0 11). On the other hand, in C6 glioma cells, MG at this
concentration induced an increase in glutamate uptake
activity (Figure 5(b)), but AG coincubation was also able to
prevent this effect. No changes were observed in the content
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Figure 1: Glyoxalase 1 expression and activity are significantly higher in primary astrocytes than in C6 cells. Rat primary astrocyte cultures
and C6 glioma cells were exposed to control conditions at 24 h. Glyoxalase 1 expression (a), glyoxalase 1 activity (b), and glyoxalase 1
expression/activity ratio (c). In (a) and (c), the control value of C6 cells is assumed as 100%. Each value represents mean ± standard error
of three independent experiments performed in duplicate from Western blot analysis and six independent experiments performed in
triplicate from glyoxalase 1 activity assays in both cell cultures. Insets are representative immunoblots for glyoxalase 1 (GLO1) or actin.
GLO1 appears as a doublet band, in astrocyte samples, or a single band, in C6 samples, with an estimated size of approximately 23 kDa.
Data were analyzed by Student’s t-test, assuming p < 0 05 (a, b). ∗Significantly different from astrocytes.
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of glutamate transporters in C6 glioma cells: GLAST
(Figure 5(d)), GLT-1 (Figure 5(f)), or EAAT3 (Figure 5(h)).
3.7. Carbenoxolone (CBX) Prevents MG Toxicity in
Astrocytes. Phase contrast and PI uptake fluorescent imaging
were used to evaluate MG toxicity (at 1mM) in primary
astrocyte and C6 glioma cultures (Figure 6). PI-positive cell
counting by microscopy showed increased staining of astro-
cytes (panels c and d) and C6 glioma cultures (panels i and
j) following incubation with MG. Notice that we did not
detect significant changes when mean PI uptake was mea-
sured by fluorimetry in the cell cultures incubated with MG
at 1mM, as shown in Figure 2(c). This apparent discrepancy
reveals differences in the sensitivity and cell specificities with
these different approaches in cell preparations.
As these cultures present significant differences in gap
junction expression and function, we investigated whether
the gap junctions could be involved in MG-induced alter-
ations. In fact, CBX, a gap junction inhibitor was able to
block the damage induced by MG (panel f), in astrocytes
but not in C6 glioma cells (panel l).
4. Discussion
Our data showing the direct effect of MG on primary astro-
cytes indicate that these cells are very resistant to high
concentrations of MG, when compared to neurons [12],
possibly due to an efficient astrocyte glyoxalase system.
Herein, we observed that glyoxalase 1 activity and expres-
sion are higher in astrocytes than in C6 glioma cells. The
cytosolic glyoxalase system is responsible for preventing
dicarbonyl stress and consists of two consecutive reactions;
the first reaction is catalyzed by glyoxalase 1, in a rate-
limiting step, where the substrate hemithioacetal, formed
by nonenzymatic condensation of methylglyoxal and
GSH, is converted into lactoylglutathione. In the second
reaction, which is catalyzed by glyoxalase 2, GSH and lac-
tate are released [6].
We found that the highest concentrations of MG signifi-
cantly decreased the cell viability and survival of astrocyte
cultures after 24 h of incubation. Therefore, for the 24 h
assays, we chose high concentrations of MG concentrations
(0.4 or 1mM), but these were unable to compromise cell
viability during this time. Moreover, similar nonphysiologi-
cally elevated concentrations of MG have been used in
several other studies and models to investigate the glycation
processes mediated by this compound [5, 12, 24–26]. Note
that apparently MG does not affect cell viability linearly in
C6 glioma cells. Based on MTT reduction and PI uptake
assays, 4mM MG is less toxic than 2mM; however, the
mechanism responsible for this unexpected result in C6 cells
is unclear at the moment.
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Figure 2: Effect of MG on cell viability and survival in astrocytes and C6 cells. MTT reduction (a), NR incorporation (b), and PI incorporation
(c) were performed to assess cellular viability after 24 h of MG exposure. In the MTT reduction and NR incorporation assays, each value
represents mean ± standard error of four independent experiments performed in triplicate from astrocytes and C6 cells, assuming the
control value as 100%. Values of fluorescence intensity for PI/field are expressed as the mean ± standard error of three independent
experiments performed in triplicate. Data from each cell culture were analyzed by one-way ANOVA followed by Dunnett’s test, assuming
p < 0 05. ∗Significantly different from control.
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When we evaluated the glyoxalase 1 response to MG
treatment, we observed an increase in activity in astrocytes
at 1mM that was not accompanied by any alteration in the
enzyme’s expression. MG, at this concentration, increased
the GSH content and AG was able to block these increments,
suggesting that astrocytes possess an important and respon-
sive system to protect against MG toxicity. We are aware that
large increases in MG levels (or low glyoxalase 2 activity)
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Figure 3: Effect of MG exposure on glyoxalase 1 activity and expression in astrocytes and C6 cultures. Rat primary astrocyte cultures and C6
glioma cells were exposed to 0.4 or 1mM MG at 24 h. Glyoxalase 1 activity (a, b) and expression (c, d). Each value represents the mean ±
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would result in S-(D)-lactoylglutathione accumulation, keep-
ing GSH trapped and decreasing GSH availability [13]. How-
ever, in other studies of astrocyte cultures, 1-2mM MG also
increased intracellular GSH levels [12], and acrolein (a com-
pound structurally related toMG) caused a biphasic response
composed of an initial decrease in GSH content, followed by
an increase 24 h afterwards [27] that was mediated by redox-
sensitive signaling pathways (e.g., Nrf-2). Therefore, it is pos-
sible that MG, by activating such signaling pathways, could
induce GSH increment at 24 h, as we observed. Accordingly,
we did not find changes in reactive species formation, based
on DCF levels at 24 h (data not shown).
In contrast, in C6 glioma cells, we observed a decrease in
GSH levels upon MG exposure and no significant differences
were observed in glyoxalase 1 activity and content. These
findings, again, reinforce the important differences between
primary astrocytes and C6 glioma cells, commonly used to
investigate glialmetabolism [16, 18]. In fact, astrocytes exhibit
regional and functional heterogeneity in brain tissue, and cell
culture studies can partially reflect this variability. We previ-
ously showed that incorporation of glycine in proteins was
significantly decreased within 1 h and 3h of MG exposure in
C6 cells [7]. As glycine is involved in GSH synthesis [3], this
explains, at least in part, the reduction in GSH in C6 cultures.
With regard to glutamate uptake, we found an impair-
ment in glutamate uptake following MG treatment in astro-
cytes, but not in C6 cells, where an increase in glutamate
uptake was observed. Accordingly, the exposure of astrocyte
cultures to another glycating agent, glyoxal, caused a reduc-
tion in glutamate uptake activity and the formation of a
GLT-1 CML adduct [26]. Data from our laboratory show that
C6 cells cultured in high levels of glucose present increased
glutamate uptake [28], while acute hippocampal slices
exposed to MG present decreased glutamate uptake [8].
Together, these results suggest that alterations in glutamate
uptake are an important target during MG glycation. How-
ever, at this moment, we do not know the mechanism(s) that
mediate the changes in this activity. We herein evaluated
transporters’ expression only, but we are aware that these
are modulated by posttranslational changes (e.g., [29]) that
are sensitive to the redox environment (e.g., [30]), direct tar-
gets of glycation, and deserve further investigation. Results
with AG suggest glycation induced by MG, but we cannot
rule out alternative mechanisms.
Importantly, astrocytes and C6 glioma cell cultures
exhibit differences in glutamate transporter expression.
Astrocytes express and demonstrate functional activity,
especially of GLAST and GLT-1, although they can also
express EAAT3 [31]. On the other hand, although C6 cells
also express GLAST and GLT-1 [32], they exhibit signifi-
cant EAAT3 expression and activity, a characteristic of
the neuronal glutamate transporter [28, 33]. Based on
Western blotting analysis for these glutamate transporters
(see Figure 5), we found higher levels of GLAST (75%),
GLT-1 (50%), and even EAAT3 (26%) in astrocytes than
in C6 cells. However, this approach does not allow us to
evaluate the relative contribution of each EAAT to the gen-
eral cell glutamate uptake. It is possible that the different
structural specificities of these transporters and the differ-
ent susceptibilities of astrocytes and C6 cells to MG-
induced glycation may explain, in part, the differences
between these cells. However, at this time, no experimental
data support this idea.
Coincubation with AG prevented the MG-induced
change in glutamate uptake activity in astrocytes and C6 gli-
oma cells cultures, indicating that these alterations are possi-
bly mediated by glycation. These functional alterations in
glutamate transporters are not related to glutamate trans-
porter expression, as MG exposure did not modify the pro-
tein expressions of GLAST, GLT-1, and EAAT3 by cells. It
is possible that MG-induced glycation does not alter protein
turnover within 24h. Moreover, astrocyte glutamate trans-
porters were not affected in an animal model of diabetes
[34], where high levels of MG may be found due to
hyperglycemia.
The ability of MG to decrease glutamate uptake in
astrocyte-containing preparations is clear; however, the
mechanism by which this occurs requires further compre-
hension. Although, direct glycation appears to be involved
in astrocyte cultures, in hippocampal slices, the decrease in
glutamate uptake was not prevented by AG incubation [8].
The current consensus is that astrocytes sense, integrate,
and respond to stimuli generated by neurons or neural
injury and that this response involves gap junctions. This
idea is supported by the fact that gap junction inhibitors
increase neuronal vulnerability when cocultures of astro-
cytes and neurons are exposed to oxidative stress [35] or
to high glutamate [36]. On the other hand, considering
the astrocytic syncytium in the brain, gap junction uncou-
pling could limit the extension of a lesion [37]. In the pres-
ent study, we investigated whether CBX, a general blocker
of gap junctions, would affect the damage induced by
MG. CBX prevented the cytotoxicity induced by MG in
astrocyte cultures. Expectedly, no changes in PI assay were
observed when C6 glioma cells were exposed to MG and
coincubated with the gap junction inhibitor [18]. These
data indicate that gap junctions have a pivotal role in
MG-induced damage in astrocytes and reinforce the idea
that the impairment of astrocyte viability, induced by
MG, involves glutamate excitotoxicity [36], supported by
reduced glutamate uptake.
On the other hand, studies in animal models of diabetes
and in vitro experiments that have determined the effects of
Table 1: AG blocks the increments in glyoxalase 1 activity and GSH
content following 1mM MG.
Astrocytes
Treatment Glyoxalase 1 activity GSH content
Control 100.0± 5.0 100.0± 16.7
MG 123.6± 2.0∗ 182.7± 33.3∗
AG 109.2± 3.4 80.9± 15.5
MG+AG 106.9± 3.4 93.6± 3.5
Rat primary astrocyte cultures were exposed to 1mMMG and 0.4mMAG at
24 h. Percentages of glyoxalase 1 activity and GSH content are shown. Each
value represents mean ± standard error of five independent experiments
performed in triplicate, assuming the control value as 100%. Data were
analyzed by one-way ANOVA followed by Dunnett’s test, assuming
p < 0 05. ∗Significantly different from control.
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Figure 5: MG alters glutamate uptake in astrocytes and C6 cultures, but not GLAST, GLT-1, and EAAT3 expression. Rat primary astrocyte
cultures and C6 glioma cells were exposed to 0.4mMMG and 0.4mMAG (a) at 24 h. Glutamate uptake (a, b), GLAST (c, d), GLT-1 (e, f), and
EAAT3 (g, h) expressions are shown. In (a), each value represents mean ± standard error of ten independent experiments performed in
triplicate with astrocytes, and in (b), six independent experiments performed in triplicate with C6 cells, assuming the control value as
100%. Data were analyzed by one-way ANOVA followed by Dunnett’s test, assuming p < 0 05. ∗Significantly different from control. In
(c)–(h), each value represents mean ± standard error of four independent experiments performed in duplicate, assuming the control value
as 100%. Insets are representative immunoblots for GLAST, GLT-1, EAAT3, or actin. Data were analyzed by Student’s t-test, assuming
p < 0 05.
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high glucose levels on astrocytes’ cultures [38, 39], as well as
the AGE-albumin treatment of aortic endothelial cells [40],
demonstrate that these compounds reduce gap junction
communications. Although it is clear that the glycation pro-
cess is involved in the mediation of MG astrocyte toxicity in
cultures, it is unclear, at this moment, whether this involves
AGE/RAGE signaling. This issue deserves further investiga-
tion in models of long-term MG exposure.
It is important to mention some limitations in this study.
Firstly, we used a single commercial source of MG, and pos-
sible impurities may compromise findings. Secondly, we are
aware that supraphysiological levels of MG limit the rele-
vance of these results. In this context, further experiments
using glyoxalase 1 silencing, as performed in other studies
[12], would complement our understanding of the glyoxalase
system. Finally, we focused on the effect of MG on glyoxalase
1 activity and quantity, but the effect on glyoxalase 2 also
requires investigation, particularly on D-lactate levels, in
order to obtain a clearer picture. Regardless of these limita-
tions, our results contribute to our understanding regarding
MG biochemistry and toxicity.
A schematic representation of our results in primary
astrocytes is shown in Figure 7, where MG (a glycolytic
derivative) causes protein glycation, in turn, leading to
an astrocyte response (increase in glyoxalase 1 activity and
glutathione levels). On the other hand, signals of astrocyte
suffering are indicated by decreased cell viability (as demon-
strated by MTT reduction assay, NR uptake, and PI
A
B
C
D
E
F
G
H
I
J
K
L
Control
Astrocyte
C6
MG MG+CBX
Figure 6: CBX protects astrocyte cultures from MG-induced cytotoxicity. Representative fields of astrocytes and C6 cultures treated with
1mM MG for 24 h in the presence of PI. CBX was added 15min before MG exposure, and cells were then coincubated with MG for 24 h.
Phase contrast and nuclear fluorescent staining are shown under control conditions (A, B, G, H), MG exposure at 1mM (C, D, I, J), and
1mM MG + 0.1mM CBX (E, F, K, L). All images are representative fields of at least three experiments, carried out in triplicate. Scale
bar = 50μm.
Protein
glycation
Glucose MG GLO1GSH
AG
Gap junction
Cell viability
Glu GluEAAT
AG
Figure 7: Schematic representation of the effect of methylglyoxal (MG) on astrocytes. Methylglyoxal (MG), a glycolytic derivative, causes
protein glycation. Glyoxalase 1 (GLO1) activity and glutathione (GSH) levels increased following MG exposure, and glutamate (Glu)
uptake activity is decreased. These alterations are blocked by aminoguanidine (AG). A decrease in cell viability is also observed, which is
mediated by gap junctions.
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incorporation) and altered glutamate uptake activity, which
is also mediated by gap junctions, as represented in Figure 7.
5. Conclusions
MG exposure impairs primary astrocyte viability, as evalu-
ated by different assays. Astrocytes respond acutely to MG
elevation by increasing the activity of glyoxalase 1 and GSH
levels. This response, in part, may sustain cell viability and
survival. In contrast, C6 glioma cells show signs of resistance
against MG without significant changes in the glyoxalase sys-
tem. AG coincubation provided evidence that MG toxicity is
mediated by glycation. Glutamate uptake activity is an
important target of MG glycation, and a significant decrease
in glutamate transport is observed in astrocytes, without
associated changes in the protein expression of major gluta-
mate transporters. CBX, a general gap junction inhibitor,
prevented the cytotoxicity induced by MG in astrocyte cul-
tures. Therefore, our data reinforce the idea that astrocyte
viability depends on gap junctions and that impairments
induced by MG involve glutamate excitotoxicity. The sus-
ceptibility of astrocytes to MG emphasizes the importance
of this compound in the brain reactions to neurodegenera-
tive diseases, where neuronal damage induced by MGmay be
aggravated by the commitment of the cells responsible for
MG clearance.
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